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Abstract
Osteoporosis is a common polygenic disease and global healthcare priority but its genetic basis remains largely unknown.
We report a high-throughput multi-parameter phenotype screen to identify functionally significant skeletal phenotypes in
mice generated by the Wellcome Trust Sanger Institute Mouse Genetics Project and discover novel genes that may be
involved in the pathogenesis of osteoporosis. The integrated use of primary phenotype data with quantitative x-ray
microradiography, micro-computed tomography, statistical approaches and biomechanical testing in 100 unselected
knockout mouse strains identified nine new genetic determinants of bone mass and strength. These nine new genes
include five whose deletion results in low bone mass and four whose deletion results in high bone mass. None of the nine
genes have been implicated previously in skeletal disorders and detailed analysis of the biomechanical consequences of
their deletion revealed a novel functional classification of bone structure and strength. The organ-specific and disease-
focused strategy described in this study can be applied to any biological system or tractable polygenic disease, thus
providing a general basis to define gene function in a system-specific manner. Application of the approach to diseases
affecting other physiological systems will help to realize the full potential of the International Mouse Phenotyping
Consortium.
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Introduction
Studies of extreme phenotypes in humans have been instru-
mental in identifying molecular mechanisms underlying rare single
gene disorders as well as common and chronic diseases including
diabetes and obesity. Such studies have resulted in novel
treatments that revolutionize the lives of affected individuals [1–
4]. Collection of suitable cohorts, however, is expensive and takes
many years to achieve, and progress has been limited to conditions
in which simple and quantitative phenotypes can be defined [4–7].
By analogy, we hypothesized that an organ-specific extreme
phenotype screen in knockout mice would more rapidly identify
new genetic determinants of disease and also provide in vivo models
to elucidate their molecular basis. The International Knockout
Mouse Consortium (IKMC) has now established an ideal resource
of mutant ES cells to test this hypothesis [8,9].
The skeleton represents a paradigm organ system and
osteoporosis is an important global disease ideally suited to such
an approach. Osteoporosis is the commonest skeletal disorder
affecting hundreds of millions of people worldwide and costing
tens of billions of pounds each year [10]. Between 50 and 85% of
the variance in bone mineral density (BMD) is genetically
determined [11], but only 3% is accounted for by known genetic
variation [12] and the vast majority of genes involved remain to be
identified [13]. Current treatments reduce fracture risk by only
25–50% [14,15] and thus there is urgent need to define new
pathways that regulate bone turnover and strength in order to
identify novel therapeutic targets. Accordingly, application of an
extreme phenotype approach to study skeletal disorders in humans
has already led to discovery of SOST (ENSG00000167941) and
LRP5 (ENSG00000162337) as critical regulators of Wnt signaling
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in bone [5,7,16] and resulted in development of new drugs to
stimulate bone formation [17].
The Wellcome Trust Sanger Institute Mouse Genetics Project
(MGP) is undertaking high-throughput production of knockout
mice using targeted ES cells generated by the IKMC. Knockout
mice are generated using a knockout-first conditional gene
targeting strategy (Figure S1), in which expression from the
targeted allele can be investigated by X-gal staining for LacZ gene
expression [9] (Figure S2). Each mouse undergoes a broad-based
primary screen to identify developmental, anatomical, physiolog-
ical and behavioral phenotypes [18–20]. A critical challenge now
is to enhance this initial screening by developing organ- or disease-
specific approaches [21] that are essential to identify biologically
significant and functionally relevant phenotypes rapidly and cost-
effectively for the benefit of the scientific community [18,19,21].
We, therefore, developed high-throughput skeletal phenotyping
methods and prospectively studied 100 consecutive unselected
mutant strains from the MGP. Using this approach, we discovered
nine new genetic determinants of bone mass and strength and
identified a novel functional classification of bone structure. These
conditional knockout mice [9] can now be used to investigate cell-
specific gene function and identify new regulatory pathways in the
skeleton. The strategy can be applied to other physiological
systems and complex diseases, thus realizing the full potential of
the International Mouse Phenotyping Consortium.
Results
Broad primary phenotype screening
Mice generated by the MGP pipeline undergo a broad primary
phenotype screen followed by terminal collection of blood and
tissue at 16 weeks of age [20]. The screen is conducted on viable
homozygote mutants, or heterozygotes in cases of embryonic
lethality, and reports 233 variables relating to 28 physiological
systems that include embyrogenesis; reproduction; growth; neu-
rological; behaviour; sensory; skeleton; muscle; gastrointestinal
and hepatobiliary; cardiovascular; endocrine; adipose; metabo-
lism; haematopoietic; immune; skin and pigmentation; respiratory;
and renal. Parameters relevant to the skeleton include body length,
x-ray skeletal survey, dual energy x-ray absorptiometry (DEXA)
analysis of BMD and biochemical measures of mineral metabo-
lism. Tissues in which the targeted gene is expressed are
determined by staining for lacZ reporter gene expression in
heterozygous mice (Figure S2). To extend this broad initial screen,
we incorporated novel imaging, statistical and biomechanical
approaches for the specific and sensitive detection of functionally
important skeletal abnormalities (Figure S3).
Generation of normal reference data
In order to establish strain-specific reference ranges for these
new approaches, limbs from 16 week-old female C57BL/6
(B6Brd;B6Dnk;B6N-Tyrc-Brd) wild-type mice (n = 77) were obtained
from 18 control cohorts. Normal ranges for six independent
parameters of bone structure were obtained using Faxitron x-ray
point projection microradiography and micro-computed tomog-
raphy (micro-CT) (Fig. 1 and Figure S4). Bone mineral content
(BMC), bone length and cortical bone thickness were determined
by x-ray microradiography and measures of trabecular bone
volume per tissue volume (BV/TV), trabecular number (Tb.N)
and trabecular thickness (Tb.Th) by micro-CT (Fig. 1). Reference
data were also obtained for six biomechanical parameters (Fig. 2
and Figure S5). The yield, maximum and fracture loads, stiffness
and the proportions of energy dissipated prior to maximum load
and fracture were determined from load displacement curves
obtained in destructive 3-point bend tests (Fig. 2).
Validation of phenotyping methods
Limbs from 16 week-old female knockout mice in an identical
C57BL/6 genetic background were obtained prospectively from
the MGP pipeline (n = 100 unselected knockout strains, 2–6 mice
per strain) and analyzed by x-ray microradiography, micro-CT
and 3-point bend testing. Serendipitously, one of the 100
unselected strains was a homozygous knockout of Sparc (EN-
SMUSG00000018593), which encodes the extracellular matrix
glycoprotein osteonectin. Deletion of Sparc is known to cause low
bone turnover osteopenia resulting in weak and brittle bone with a
higher mineral-to-matrix ratio due to reduced bone matrix content
[22,23]. Thus, Sparc knockout mice represented a well-character-
ized positive control for validation of our approach. Consistent
with the reported phenotype [22,23], we identified that Sparc
knockout mice had reduced BMD and BMC with loss of
trabecular bone but preservation of cortical bone thickness (Fig. 1
and Table S1), resulting in weak and brittle bone of reduced
stiffness (Fig. 2). We also identified short stature in Sparc knockout
mice (Fig. 1A), a parameter not investigated in previous studies.
These findings validate the use of complementary and multi-
parameter imaging together with biomechanical methods as a
rapid and specific phenotyping approach to identify biologically
significant and functionally relevant skeletal abnormalities using a
minimal number of animals (n = 2).
Phenotyping of 100 knockout strains
To identify new genetic determinants of bone mass and
strength, limbs from 100 knockout strains were analyzed for each
structural and biomechanical variable. X-ray microradiography
and micro-CT imaging identified 19 knockout strains in which at
least one structural parameter was .2.0 standard deviations (SD)
from the reference mean (Fig. 3, Figure S4 and Table S1). To
ensure that significant abnormal phenotypes resulting from
simultaneous but smaller variances in any of the six parameters
were not overlooked, Mahalanobis distances were calculated as
detailed in the methods and principal component analysis
performed to identify multivariate outliers [24–27]. These studies
identified 40 strains with outlier Mahalanobis distances (P,0.025),
24 of which had not been identified by analysis of individual x-ray
microradiography or micro-CT values alone (Fig. 3 and Table S1).
Author Summary
Chronic disease represents a global healthcare burden but
its genetic basis is largely unknown. To address this, a
massive international investment is generating a resource
of mutant mice to investigate the function of every gene.
Although current characterization of mutants is broad-
based, it lacks specificity. Here, we describe a new and
rapid functional screening approach to identify genes
involved in disease susceptibility. Using bone and osteo-
porosis as a paradigm, we identify nine new genes that
determine bone structure and strength from a screen of
100 knockout mice. Deletion of five of the genes leads to
low bone mass, whereas deletion of four results in high
bone mass. We also report a novel functional classification
that relates bone structure to bone strength and opens the
field to collaborative research between material scientists,
bioengineers and biologists. Our rapid throughput phe-
notyping approach can be applied to complex diseases in
other physiological systems, thus realizing the full poten-
tial of the International Mouse Phenotyping Consortium.
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The MGP broad primary phenotype screen independently
annotated 17 of these knockout strains with skeletal abnormalities
(Table S1). Nine of the strains were also identified as outliers by x-
ray microradiography, micro-CT or statistical methods whereas 8
did not display any abnormalities (Fig. 3).
The biomechanical significance of the 43 outlier phenotypes
identified by imaging (n= 19, Faxitron and micro-CT) and
statistical (n = 24, Mahalanobis analysis but excluding Faxitron
and micro-CT) approaches, together with the 8 additional strains
identified only in the MGP primary screen, was investigated
(Fig. 3). Twelve of the 51 strains had at least one biomechanical
parameter .2.0 SD from the reference mean (Fig. 3, Figure S5
and Table S1). However, 2 of these 12 strains had only minor
abnormalities of bone morphology in the primary screen and were
normal when investigated by x-ray microradiography, micro-CT
and principal component analysis. Destructive 3-point bend
testing of bones from the remaining 49 strains identified a further
7 with a single outlier biomechanical parameter but no other
abnormality (Fig. 3 and Table S1).
In summary, the broad primary phenotype screen together with
x-ray microradiography, micro-CT and statistical analysis identified
knockout strains with at least one abnormal bone-related param-
eter. The addition of functional biomechanical testing demonstrated
that 10 of these strains had major phenotypes affecting both the
structure and strength of bone. Three of these carried heterozygous
mutations (Asxl1 (ENSMUSG00000042548), Setdb1 (ENSMUS-
G00000015697) and Trim45 (ENSMUSG00000033233)) while the
rest were homozygotes (Bbx (ENSMUSG00000022641), Cadm1
(ENSMUSG00000032076), Fam73b (ENSMUSG00000026858),
Prpsap2 (ENSMUSG00000020528), Slc38a10 (ENSMUSG-
00000061306), Sparc and Spns2 (ENSMUSG00000040447)).
The primary phenotype database (http://www.sanger.ac.uk/
mouseportal/) was interrogated for each of the strains identified
with major skeletal phenotypes (Table 1).
Accuracy of rapid throughput skeletal phenotyping
The sensitivities, specificities and predictive values of each
phenotyping method at a statistical threshold of.2.0 SD and 95%
confidence limit were calculated to determine their ability to
identify the 10 strains with major phenotypes. X-ray microradi-
ography was the most accurate, identifying 8 of the 10 strains.
Additional use of micro-CT and Mahalanobis analysis was
required to identify the remaining 2 strains (Table S2). The
MGP primary phenotype screen identified 5 of the 10 abnormal
strains. Thus, addition of organ-specific imaging, statistical and
biomechanical analyses to the primary phenotype screen resulted
in increased sensitivity and specificity (Table S2), demonstrating
the advantage of a complementary multi-parameter approach.
Correlations between imaging and biomechanical parameters
were also determined to investigate relationships between bone
structure and strength (Figure S6). Bone strength correlated
strongly with BMC, cortical thickness and bone length but not
with BV/TV, Tb.Th or Tb.N. Furthermore, there was no
significant relationship between bone structural parameters
determined by x-ray microradiography and micro-CT, thus
demonstrating independence of the two techniques. Consistent
with sensitivity, specificity and predictive value data (Table S2)
these findings demonstrate that mineralization and cortical bone
parameters determined by x-ray microradiography are excellent
Figure 1. Faxitron x-ray microradiography and micro-CT. A, Faxitron femur images from WT and Sparc mice (arrows indicate location for
cortical bone thickness measurement, bar = 1 mm). B, Bone mineral content (BMC) in WT and Sparcmice. Pseudo-colored images in which lower BMC
is in green and yellow and higher BMC is red and purple. C, Cumulative frequency histograms of BMC in n= 77 female, 16 week-old WT (mean
62.0SD reference range in grey) and Sparc mice (red line). The median grey level is indicated by the dotted line. Graphs showing mean (solid line),
1.0SD (dotted line) and 2.0SD (grey box) for D, median grey level BMC, E, bone length and F, cortical thickness in WT (n = 77) mice. Values for Sparc
(n = 2) in red. Micro-CT tibia images from G, WT and H, Sparc mice (bar = 1 mm). Graphs showing mean, 1.0SD and 2.0SD for I, BV/TV, J, trabecular
number (Tb.N) and K, trabecular thickness (Tb.Th) in WT mice. Values for Sparc in red.
doi:10.1371/journal.pgen.1002858.g001
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predictors of bone strength determined by 3-point bend testing,
whereas trabecular bone structure determined by micro-CT is not.
Importantly, trabecular bone parameters determined by micro-
CT may represent good predictors of bone strength at sites of
predominantly cancellous bone such as the vertebra or in response
to age-related bone loss, although these possibilities were not
investigated.
Functional classification of bone structure
Biomechanical analysis of wild-type mice and the 10 knockout
strains with major phenotypes enabled four distinct biomechanical
categories to be identified (Fig. 4). Normal bone had a stiffness of
30.264.1 N/mm (mean 6 SD) with the capability to resist
loading up to a yield load of 8.960.9 N (mean 6 SD) and
maximum load of 10.760.9 N (mean 6 SD), prior to fracture at a
load of 6.461.7 N (mean 6 SD). These material properties of
normal bone represent an optimised compromise between
strength and flexibility that allows dissipation of 86.2% of energy
prior to failure and limits the structural damage at fracture (Table
S1).
Bones from strains with major phenotypes clustered into three
abnormal biomechanical categories. Bones from Bbx, Cadm1 and
Fam73b knockout mice were weak but flexible with reduced
maximum load but the capability to bend and dissipate energy
prior to fracture (Fig. 4B). Sparc, Prpsap2 and Slc38a10 bones were
weak and brittle with reduced maximum load and lacking the
capability to bend and dissipate energy prior to fracture (Fig. 4C).
Asxl1, Trim45, Spns2 and Setdb1 bones were strong but brittle with
an increased maximum load but were unable to bend and dissipate
energy prior to fracture (Fig. 4D). A plot of the proportion of
energy dissipated prior to fracture versus maximum load clearly
separates these categories of bone strength (Fig. 4E). Further
analysis demonstrated that Bbx, Cadm1, Fam73b Sparc, Prpsap2 and
Slc38a10 bones have low BMC, whereas Asxl1, Trim45, Spns2 and
Setdb1 bones have high BMC (Fig. 5). To determine whether these
three categories of abnormal bone strength were related to a
further morphological parameter known to have an important role
for the biomechanical properties of long bones, we investigated
their relationship with mid-diaphyseal diameter (Fig. 6). As
expected [28], in WT mice mid-diaphyseal diameter correlated
with fracture load and the proportion of energy dissipated prior to
fracture. However, bones from the mutant strains identified with
major skeletal phenotypes clustered into the same three abnormal
categories, further demonstrating the validity of this functional
classification.
Investigation of the biological activities of the 10 genes and their
possible roles in bone indicates a broad diversity of function that
was not clearly related to phenotype (Table 1), thus reinforcing the
Figure 2. Biomechanical analysis. A, Load-displacement curve from a WT tibia showing yield load, maximum load, fracture load and gradient of
the linear elastic phase (stiffness). B, Curves from WT and Sparc. C, Graphs showing mean (solid line), 1.0SD (dotted line) and 2.0SD (grey box) for
yield load, maximum load, fracture load and stiffness of WT (n = 77) mice. Values for Sparc in red. D, Energy dissipated prior to maximum load (DEML,
purple) and elastic stored energy at maximum load (ESEML, yellow). E, Graph showing mean61.0SD and 2.0SD for the proportion DEML/(DEML+ESEML)
prior to maximum load for WT mice. Value for Sparc in red. F, Energy dissipated prior to fracture (DEF, purple) and elastic stored energy at fracture
(ESEF, yellow). G, Graph showing mean 61.0SD and 2.0SD for the proportion DEF/(DEF+ESEF) prior to fracture for WT mice. Value for Sparc in red. y-
axis scale reflects angular transformation to normalize data distribution.
doi:10.1371/journal.pgen.1002858.g002
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importance of an unbiased screening approach for identification of
gene function in both homozygous and heterozygous mutants. In
summary, a functional classification of four categories of bone
structure was defined. Normal bone is strong and flexible with a
normal mineral content, whereas abnormal bone is either (i) weak
but flexible with low BMC, (ii) weak and brittle with low BMC or
(iii) strong but brittle with high BMC.
Discussion
We have identified 10 genes with diverse and unrelated
functions, the deletion of which resulted in major skeletal
abnormalities. By adopting a multi-parameter phenotyping
approach, we identified a new functional classification of bone
structure based on its mineral content, strength and ductility that
clarifies understanding of skeletal physiology and pathology, and
which maps directly to human disease. As a result of evolutionary
pressure, bone structure represents an optimal compromise
between strength and flexibility that requires contributions from
many diverse genes. Continuous bone remodeling enables the
skeleton to adjust this compromise in response to changing
physiological and environmental pressures [29,30]. The current
studies demonstrate that loss of function of individual genes can
disrupt this optimal compromise resulting in skeletal phenotypes
that cluster into three functionally distinct categories.
Postmenopausal osteoporosis is characterized by weak but
flexible bone with low mineral content [31] and three of the
identified knockout strains (Bbx, Cadm1, Fam73B) had phenotypes
in this category. Bbx encodes a conserved transcription factor that
contains a SOX-TCF HMG-box [32–36]. Family members
include SRY-related Sox genes that are implicated in skeletal
dysplasias [37,38] and the TCF/LEF transcription factors that
mediate Wnt/b-catenin signaling [39], a key pathway implicated
in osteoporosis and osteoarthritis [40–43]. Cadm1 encodes a trans-
membrane glycoprotein adhesion molecule of the immunoglobulin
superfamily [44] for which a number of disparate functions have
been reported including; tumor suppression [45], synapse devel-
opment [46], behavioral regulation [47], T cell adhesion [48],
mast cell interactions [49], and spermatogenesis [50]. However, no
function in the skeleton has been reported. Fam73B encodes a
conserved membrane protein of unknown function. These findings
indicate that deletion of genes encoding proteins with diverse and
unrelated functions can result in similar defects of bone strength
and mineralization.
Disorders of bone matrix as typified by osteogenesis imperfecta
[51] are characterized by bone that is weak and brittle with low
BMC, and three of the strains (Prpsap2, Slc38a10, Sparc) displayed
this phenotype. Prpsap2 encodes the non-catalytic inhibitory
subunit of phosphoribosylpyrophosphate synthetase [52], and is
required for synthesis of purine and pyrimidine nucleotides, the
amino acids histidine and tryptophan, and the coenzyme
nicotinamide adenine dinucleotide [53]. Its function in the
skeleton is unknown, although a recent study proposed PRPSAP2
as a candidate oncogene in osteosarcoma tumorigenesis [54].
Slc38a10 encodes a proposed sodium-coupled neutral amino acid
membrane transporter [55] that may act as a cell volume regulator
in mesenchyme [56]. The severe growth defect in Slc38a10
knockout mice suggests a critical function in chondrocytes, which
mediate linear growth by cell volume expansion during hypertro-
phic differentiation [57]. Furthermore, related transporters have
already been implicated in human skeletal disease. SLC35D1 is
critical for chondroitin sulphate synthesis and mutations cause
Schneckenbecken skeletal dysplasia [58]. Mutations in SLC26A2,
cause four distinct chondrodysplasia syndromes [59] and empha-
size the key role of these transporters in endochondral ossification.
Sparc encodes the well-described extracellular matrix glycoprotein
osteonectin and its deletion resulted in the characteristic and
expected phenotype [22,23] of weak and brittle bone with low
BMC. These findings highlight the importance of enzymes,
transporters and structural proteins to the functional integrity of
bone matrix.
Figure 3. Knockout strains with abnormal skeletal phenotypes. Venn diagram showing strains with at least one outlier structural parameter
.2.0SD from the C57BL/6 reference mean determined by Faxitron, micro-CT, Mahalanobis distance calculation or primary phenotype screening.
Strains with at least one outlier biomechanical parameter in blue. 10 strains with major phenotypes are highlighted in boxes.
doi:10.1371/journal.pgen.1002858.g003
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Table 1. Functions of genes identified as determinants of bone strength.
Gene Expression Protein Biological Function Skeletal Function
Primary Phenotyping
Features Ref
Weak but Flexible (Low BMC)
Bbx
(NM_027444)
Brain, spinal
cord, peripheral
nervous system,
testis and cartilage
Bobby sox homolog
(HMG box transcription
factor)
Unknown, but related
protein family members
include SRY-related Sox
genes and TCF-LEF
mediators of Wnt
signalling
Sox genes and Wnt
signalling regulate
skeletal development
and bone formation,
mineralization and
turnover. Bbx may
have a related
function
Homozygotes viable
and fertile.
Decreased lean body
mass and cardiac weight,
increased plasma IgA.
Skeletal abnormalities
include decreased nose to
tail length, dental
asymmetry and low BMD.
[28–35]
Cadm1
(NM_001025600)
Ambiguous pattern
in stomach, testis,
nasal epithelia and
bone, but absent
from cartilage
Cell adhesion
molecule 1 (immuno-
globulin superfamily -
cell adhesion molecule)
Tumour suppressor gene
with a role in retinoid-
regulated synapse
development
Unknown Homozygous females
fertile, but males infertile.
No additional
abnormalities.
[36–38]
Fam73b
(NM_001242407)
Most tissues
including cartilage
but not bone
Family with sequence
similarity 73
member B (membrane
protein with
conserved 500–600
amino acid domain)
Unknown Unknown Homozygotes viable and
fertile.
Decreased body weight
and lean body mass and
increased susceptibility to
infection following
citrobacter challenge,
decreased serum total
protein and albumin.
Skeletal abnormalities
include decreased body
length, low BMD in
females and abnormal
tooth morphology in
males.
Weak and Brittle (Low BMC)
Prpsap2
(NM_001164244)
Most tissues
including cartilage
but not bone
Phosphoribosyl
pyrophosphate
ynthetase-associated
protein 2
(non-catalytic subunit
of phosphorib-
osylpyrophosphate
synthetase)
Catalyzes formation of
phosphoribosylpyroph-
osphate substrate for
synthesis of purine
and pyrimidine
nucleotides
Candidate oncogene
in osteosarcoma
Homozygotes
viable and fertile.
Increased rearing
in males and
decreased plasma IgG1.
[39,40]
Slc38a10
(NM_001164798)
Most tissues
including bone
and cartilage
Solute carrier family
38 member 10
(sodium-coupled
neutral amino
acid transporter)
Proposed as a cell
volume regulator in
mesenchyme
Growth defect suggests
role in hypertrophic
chondrocytes, which
mediate growth by cell
volume expansion
Homozygotes viable and
fertile.
Decreased fat and
leanmass, increased
oxygen consumption
and energy expenditure,
reduced serum amylase
in females, increased
creatinine and low
albumin in males.
Skeletal abnormalities
include reduced body
length and
decreased BMD.
[41–43]
Sparc
(NM_009242)
Ubiquitous Secreted protein
acidic and rich in
cysteine
(osteonectin -
extracellular matrix
glycoprotein)
Cell migration and tissue
remodelling during
development
and in response to injury
Regulation of collagen
assembly during bone
formation and turnover,
regulation of osteoclast
maturation and function
Homozygotes viable and
fertile.
Cataracts.
Skeletal abnormalities
include abnormal
teeth and decreased BMD.
[22,23]
Strong but Brittle (High BMC)
Asxl1
(NM_001039939)
Most tissues
including bone
and cartilage
Additional sex -
combs-like 1
(conserved polycomb
chromatin-binding
protein)
Cooperates with heteroch-
romatin protein-1 to
repress retinoic acid
signaling. Mutations cause
Bohring-Opitz syndrome
Regulates Hox genes
during axial patterning,
suggesting role in
skeletal development
Homozygous lethal due to
craniofacial defects.
Heterozygotes viable and
fertile.
Minor defects in lumbar
and sacral vertebrae in
heterozygotes.
[44–48]
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Diseases of high bone mass are rare and include sclerosteosis
due to deletion of SOST [60] and autosomal dominant high bone
mass due to gain-of-function mutations in LRP5 [61]. They are
characterized by bone that is strong but brittle with high BMC,
and four of the knockout strains (Asxl1, Setdb1, Spns2, Trim45)
displayed such a phenotype. Asxl1 encodes a polycomb protein
that interacts with heterochromatin protein-1 [62] and is required
for regulation of Hox genes during axial patterning [63], suggesting
a role in skeletal development [64,65]. Indeed, ASXL1 heterozy-
gous nonsense mutations were recently described to cause
Bohring-Opitz syndrome [66], a developmental disorder charac-
terized by mental retardation, impaired intrauterine growth,
trigonocephaly and wrist and metacarpophalangeal joint abnor-
malities. Although the disease mechanism is unknown, craniofacial
defects identified in homozygous Asxl1 knockout mice suggest that
mutations in Bohring-Opitz syndrome result in a mutant protein
with dominant-negative activity. Setdb1 encodes a histone H3
methyltransferase that regulates gene silencing [67,68]. Although
found to be expressed in cartilage but not bone in the primary
phenotype screen, other studies demonstrated Setdb1 expression in
osteoblasts and suggested a role in lineage commitment and
differentiation [69,70]. Spns2 encodes a sphingosine 1-phosphate
(S1P) transporter [71] that is essential for S1P secretion. S1P binds
to the G-protein coupled receptors, S1PR1 and S1PR2, and
regulates osteoclast [72,73] and osteoblast [74] precursor cell
recruitment and migration. Thus, control of S1P secretion by
Spns2 represents a novel mechanism that couples bone resorption
and formation [75]. Trim45 is a member of the tripartite protein
family, many of which act as ubiquitin or SUMO E3 ligases [76–
78]. Although restricted to brain and testis in the primary
phenotype screen, human studies demonstrate that Trim45 is more
widely expressed [79]. Little is known about its function, although
one study indicates Trim45 interacts with AP-1 and inhibits activity
of the MAP kinase pathway [79]. The physiological significance of
these findings and the role of Trim45 in the skeleton are unknown,
although AP-1 proteins are key regulators of osteoblast and
osteoclast differentiation and function [80,81]. These findings
emphasize the importance of lineage commitment, control of cell
differentiation and coupling of both osteoblasts and osteoclasts in
high bone mass disorders.
In the context of osteoporosis, our identification of many new
genes that determine bone strength, and which otherwise could
not be predicted, is consistent with studies indicating that diverse
genetic polymorphisms result in small effects on phenotype
[11,12,82,83]. Accordingly, and in line with current understanding
that only 3% of the heritability of BMD is accounted for by known
genetic variation [12], none of the genes identified in this study
have been recognized in osteoporosis genome-wide association
studies [84]. We hypothesize, therefore, that unbiased multi-
parameter and functional phenotyping of knockout mice has the
power to identify many of the major genes that determine bone
strength. Ultimately, this approach is likely to identify several
genes from a single signaling pathway with an important role in
the control of bone mass and strength. This has the advantage of
independently confirming critical pathways and the potential to
identify several alternative therapeutic targets. Importantly,
however, the approach has limitations. The study of knockout
mice can only identify phenotypes that result from gene deletion
but cannot identify genes that only cause abnormalities when they
harbor gain-of-function or dominant-negative mutations. Further-
more, the strategy does not include challenges such as ageing that
may reveal additional phenotypes. However, if such provocative
challenges were to be incorporated into screening approaches they
would inevitably increase costs and limit throughput.
Our findings resulted from development and refinement of a
rapid-throughput phenotyping algorithm to identify knockout
Table 1. Cont.
Gene Expression Protein Biological Function Skeletal Function
Primary Phenotyping
Features Ref
Setdb1
(NM_001163641)
Restricted pattern
including cartilage
but not bone
SET (Su(var)3-9,
Enhancer-
of-zeste, Trithorax)
domain bifurcated-1
(histone-lysine N-
methyltransferase)
Regulates gene silencing Expressed in osteoblasts
with possible role in
lineage
commitment and
differentiation
Homozygous embryonic
lethal.
Heterozygotes viable and
fertile.
Increased natural killer
lymphocytes and CD4+ T
cells in
female heterozygotes.
[49–51]
Spns2
(NM_153060)
Restricted pattern
including cartilage
and bone
Spinster homolog 2
(spingosine-1-
phosphate transporter)
Required for secretion of
sphingosine 1-phosphate
(S1P), which binds to the
G-protein receptors, S1PR1
and S1PR2
Modulates osteoclast
and osteoblast
precursor cell
recruitment and
migration. Regulation
of S1P secretion
may represent new
mechanism to control
coupling of bone
formation to resorption
Homozygotes viable and
fertile.
Abnormal vision and
hearing, reduced blood
glucose and increased
bilirubin in males,
abnormal lymphocyte,
granulocyte and
monocyte fractions in
females.
[52–56]
Trim45
(NM_001165952)
Brain and testis Tripartite motif
containing
protein 45 (putative
ubiquitin or SUMO E3
ligase)
Interacts with AP-1 and
inhibits
MAP kinase activity
Role in the skeleton
unknown,
although AP-1 regulates
osteoblast differentiation
and
bone formation.
Homozygous lethal
due to exencephaly.
Heterozygotes viable
and fertile.
[57–61]
Table summarizing the known and proposed functions of the 10 genes which, when deleted, result in major skeletal phenotypes affecting bone structure and strength.
Patterns of gene expression and abnormalities identified by primary phenotype screening are also included.
doi:10.1371/journal.pgen.1002858.t001
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mice with major abnormalities of bone structure and strength
(Figure S3). The methods require bones from only two knockout
mice, which first undergo digital point projection x-ray microra-
diography and micro-CT determination of six parameters of bone
structure. Mahalanobis distance calculations and principal com-
ponent analysis is performed and strains with at least one
structural parameter .2.0 SD from the reference mean plus
those with outlier Mahalanobis distances (95% confidence limit)
are selected for biomechanical studies. Bones from selected strains
undergo destruction 3-point bend testing to determine six
measures of bone strength. Application of this unbiased approach
to 100 consecutive knockout strains from the MGP pipeline
identified 10% with major phenotypes affecting bone strength.
Subsequent consideration of the results of primary phenotype
screening and biological plausibility (Figure S3) allowed selection
of mice to be refined.
Inherent in this approach is the capability to alter the statistical
stringency threshold of analyses such that the number of strains for
subsequent functional studies can be adjusted according to
phenotype severity. For example, if the threshold for structural
parameters is increased from 2.0 to 3.0 SD, then 9 outlier strains
(rather than 19) are identified. Furthermore, if the confidence limit
for Mahalanobis distance is increased from 95 to 99.7% then 21
multivariate outliers (rather than 40) would be identified. Of note,
Trim45, which was recognized as an outlier only by Mahalanobis
analysis, would still be identified if the confidence limit were to be
increased to 99.7%, thus emphasizing the importance of a robust
statistical method to ensure that all functional outliers are
captured. Biomechanical analysis following application of these
more stringent thresholds would detect 8 outlier strains including
Trim45 and Sparc, resulting in the identification of 7 novel
determinants of bone mass and strength rather than 9. The
intrinsic flexibility of such a bespoke approach facilitates its
application to other biological systems or polygenic diseases.
Materials and Methods
Ethics statement
All mouse studies were undertaken by Wellcome Trust Sanger
Institute Mouse Genetics Project as part of the International
Knockout Mouse Consortium and licensed by the UK Home
Office in accordance with the Animals (Scientific Procedures) Act
1986 and the recommendations of the Weatherall report.
Primary phenotype screen
All mice generated by the MGP undergo a broad primary
phenotype screen (http://www.sanger.ac.uk/mouseportal/) that
includes measurement of body length, x-ray skeletal survey,
DEXA analysis of bone mineral density and biochemical measures
of mineral metabolism performed between 14–16 weeks of age,
and determination of the normal tissue expression pattern of the
targeted gene in 6–12 week old mice. Following primary
phenotyping, lower limbs were fixed in 70% ethanol.
LacZ reporter gene expression
The pattern of LacZ reporter gene expression was determined
in whole mount tissue preparations from heterozygous knockout
mice between 6 and 12 weeks of age. Under terminal anaesthesia,
mice were perfused with fresh cold 4% paraformaldehyde (PFA).
Tissues were fixed for a further 30 min in 4% PFA, rinsed in
phosphate buffered saline and stained with 0.1% X-gal for
48 hours at 4uC. Samples were subsequently fixed overnight in 4%
PFA at 4uC, cleared with 50% glycerol and transferred to 70%
glycerol. Specific and non-specific staining was determined in 41
tissues (Figure S2). A panel of 27 standardized images were
recorded if expression was widespread (www.sanger.ac.uk/
mouseportal).
Faxitron point projection digital x-ray microradiography
Bones from 16 week-old mice were fixed in 70% ethanol. Soft
tissue was removed from the fixed bones and digital X-ray images
were recorded at 10 mm pixel resolution using a Faxitron MX20
variable kV point projection x-ray source and digital image system
(Qados, Cross Technologies plc, Sandhurst, Berkshire, UK)
operating at 26 kV and 56 magnification [85]. Magnifications
were calibrated by imaging a digital micrometer. Bone mineral
content, bone length and cortical bone thickness were determined
Figure 4. Functional classification of bone structure. A, Load-
displacement curve from WT tibia showing 2.0SD distribution of C57BL/
6 reference range in grey. B, Curves from Bbx, Cadm1 and Fam73b mice
with weak but flexible bones and low bone mineral content (BMC). C,
Curves from Sparc, Prpsap2, and Slc38a10 mice with weak and brittle
bones and low BMC. D, Curves from Asxl1, Trim45, Spns2 and Setdb1
mice with strong but brittle bones and high BMC. E, Proportion of
energy dissipated prior to fracture (DEF/DEF+ESEF) versus maximum
load. The y-axis scale reflects angular transformation to normalise data
distribution. Strains with major phenotypes in red and individual WT
mice in black. The plot separates four functional categories of bone
structure that include normal bone which is strong and flexible with
normal BMC and the three abnormal categories in B, C, and D.
doi:10.1371/journal.pgen.1002858.g004
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Figure 5. Knockout strains with major phenotypes affecting bone structure and strength. A, Digital radiographs of femurs from WT mice
and each of the 10 knockout strains with major phenotypes (bar = 1 mm). B, Magnified images of mid-diaphysis, the region where cortical thickness
was determined (bar = 1 mm). C, Grey-scale images pseudo-coloured using a 16-colour palette in which lower BMC is in green and yellow and higher
BMC is red and purple (bar = 1 mm). D, Cumulative frequency histograms of whole femur BMC in WT mice and knockout strains: Bbx, Cadm1 and
Nine New Genetic Determinants of Bone Strength
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with coefficients of variation (CV) of 1.7%, 2.0% and 5.1%,
respectively. The relative mineral content of calcified tissues was
determined by comparison with standards included in each image
frame, which comprised: a 1 mm steel plate; a 1 mm diameter
spectrographically pure aluminum wire; and a 1 mm diameter
polyester fiber. 236862340 16 bit DICOM images were converted
to 8 bit Tiff images using ImageJ and the histogram stretched from
the polyester (grey level 0) to steel (grey level 255) standards.
Increasing gradations of mineralization density were represented
in 16 equal intervals by a pseudocolor scheme. Cortical bone
thickness was determined in at least 10 locations at the mid-
femoral diaphysis. Bone length was determined using ImageJ 1.41
software (http://rsb.info.nih.gov/ij/).
Micro-CT
Tibias were analyzed by micro-CT (Skyscan 1172a, Skyscan,
Belgium) at 50 kV and 200 mA using a 0.5 mm aluminum filter
and a detection pixel size of 4.3 mm2 [85]. Images were captured
every 0.7u, with 26averaging, through 180u rotation of each bone
and reconstructed using Skyscan NRecon software. A volume of
1 mm3 of trabecular bone was selected as the region of interest,
0.2 mm from the growth plate. Trabecular bone volume as
proportion of tissue volume (BV/TV, %, CV 18.4%), trabecular
thickness (Tb.Th, mm, CV 11.1%) and trabecular number (Tb. N,
mm21, CV 17.4%) were analyzed [86] using Skyscan CT analysis
software.
Destructive 3-point bend testing
Bones were stored and tested in 70% ethanol. Destructive 3-
point bend tests were performed on an Instron 5543 materials
testing load frame (Instron Limited, High Wycombe, Buckin-
ghamshire, UK) using custom built mounts with rounded supports
that minimize cutting and shear loads [85]. Bones were positioned
horizontally and centered on custom supports with the anterior
surface upward. Load was applied vertically to the mid-shaft with
a constant rate of displacement of 0.03 mm/second until fracture.
A span of 12 mm was used. Load-displacement curves were
plotted and yield load, maximum load and fracture load
determined. Stiffness, the slope of the linear (elastic) part of the
load-displacement curve, was calculated by the ‘‘least squares’’
method. Work energy was calculated from the area under curve at
both maximum load and fracture. Elastic stored energy at
maximum load was determined by calculating the area of a right
angled triangle with the vertex at the point of maximum load and
hypotenuse with a slope equal to that of the linear phase of the
load-displacement curve. Elastic stored energy at fracture was
similarly calculated but with the vertex of the triangle at the point
of fracture (Fig. 2). Energy dissipated at maximum load or fracture
was calculated by subtracting the elastic stored energy from the
work energy at maximum load or fracture. CVs for each
parameter were as follows: yield load (9.8%), maximum load
(8.5%), fracture load (26.6%), stiffness (13.6%), the ratio of energy
dissipated at maximum load to elastic stored energy at maximum
load (25.1%), and the ratio of energy dissipated prior to fracture to
elastic stored energy at fracture (11.0%).
Calculation of Mahalanobis distances
C57BL/6 reference ranges were generated for all Faxitron and
micro-CT measures. Outliers in multivariate data were identified
using robust Mahalanobis distances [27], which measure how far
each observation is from the center of a data cluster, taking into
account the shape of the cluster [87]. Robust Mahalanobis
distances
Fam73b mice with weak but flexible bones and low BMC (left); Prpsap2, Slc38a10 and Sparc mice with weak and brittle bones and low BMC (middle);
and Asxl1, Setdb1, Spns2 and Trim45 mice with strong but brittle bones and high BMC (right). E, Transverse sections of tibias from WT and knockout
mice imaged by micro-CT (bar = 1 mm). F, Mid-sagittal longitudinal sections of tibias from WT and knockout mice imaged by micro-CT (bar = 1 mm).
doi:10.1371/journal.pgen.1002858.g005
Figure 6. Relationship between mid-diaphyseal cortical bone
diameter and strength. A, Graphs showing mid-diaphyseal cortical
bone diameter mean (solid line), 1.0SD (dotted line) and 2.0SD (grey
box) in mutant strains with weak but flexible, weak and brittle, and
strong but brittle bones. B, Relationship between fracture load and
mid-diaphyseal cortical bone diameter. Strains with major phenotypes
in red and individual WT mice in black. The 2.0SD reference range for
each variable is represented by the grey box. The plot separates four
functional categories of bone structure that include normal bone which
is strong and flexible with normal BMC and the three abnormal
categories weak but flexible (low BMC, green), weak and brittle (low
BMC, purple) and strong but brittle (high BMC, orange). C, Relationship
between energy dissipated prior to fracture (DEF/(DEF+ESEF)) and
cortical bone diameter. The y-axis scale reflects angular transformation
to normalize data distribution. The same functional categories of bone
structure are separated by this plot.
doi:10.1371/journal.pgen.1002858.g006
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MD2i~ xi{T Xð Þð ÞC Xð Þ{1 xi{T Xð Þð ÞT
were calculated for the vector of multivariate observations xi as
described [27]. Here T Xð Þ is a robust (i.e. relatively unaffected
by outliers) estimate of the mean vector and C Xð Þ is a robust
estimate of the covariance matrix of the data set X . Under the
assumption of multivariate normality, if mouse i is from the same
population as the rest of the data then MD2i has a chi-squared
distribution with p degrees of freedom (where p is the number of
variables). Robust estimates of the mean and covariance matrix
are used so that potential outliers are not masked. The masking
effect, by which outliers do not necessarily have a large
Mahalanobis distance, can be caused by a small cluster of
outliers that attract the mean and inflate the covariance in its
direction. By replacing the sample mean and covariance with a
robust estimate, the influence of these outliers is removed and the
Mahalanobis distance is able to expose all outliers. Robust
estimates of the mean and covariance matrix were calculated
using the minimum volume ellipsoid method [87]. Given n
observations and p variables, the minimum volume ellipsoid
method seeks an ellipsoid containing
h~
nzpz1ð Þ
2
 
points of minimum volume. All analysis was conducted in the
statistical computing package R (http://www.R-project.org).
Principal Component Analysis
Principal component analysis was used as a method to visualize
multivariate data and reveal outliers by describing variation in a set of
correlated variables in terms of a new set of uncorrelated variables.
These new variables or principal components are linear combinations
of the original variables derived in decreasing order of importance so
that the first component accounts for the most variation of all possible
linear combinations. The second component is then selected so that it
accounts for as much of the remaining variance as possible (subject to
it being uncorrelated with the first component), and so on [24]. Since
the first few principal components often contain most of the variation
in the data set they can be used as a lower-dimensional summary of
the original variables.
Statistics
Normally distributed data were analyzed by Student’s t test, or
ANOVA followed by Tukey’s multiple comparison post-hoc test.
Relationships between bone structure and biomechanical mea-
sures, and between individual bone structure parameters, were
determined by Pearson correlation. P values,0.05 were consid-
ered significant. Frequency distributions of bone mineral densities
obtained by Faxitron were compared using the Kolmogorov-
Smirnov test, in which P values for the D statistic in 1024 pixel
data sets were D=.6.01 P,0.05, D=.7.20 P,0.01, and
D=.8.62 P,0.001.
Supporting Information
Figure S1 International knockout mouse consortium gene
targeting strategy. A, Global gene inactivation is achieved using
a gene-trap targeting cassette containing a LacZ gene expressing
b-galactosidase and a neomycin marker gene flanked by Flp
recombinase target sites (FRT), together with a critical exon
flanked by loxP sites (exon 3 in this example). Gene expression
from the targeted allele can be determined by X-gal staining for b-
galactosidase activity. B, Crossing targeted mice with a Flp deleter
strain removes the lacZ and neomycin genes, resulting in reversal
of the gene-trap knockout and generation of a floxed allele. C,
Mice harboring the floxed allele can be crossed with appropriate
Cre recombinase expressing strains to generate tissue-specific
knockout mice for further study.
(TIF)
Figure S2 Determination of the tissue distribution of gene
expression. A, Widespread tissue distribution of Asxl1 expression as
determined by X-gal staining of tissue preparations for lacZ
reporter gene expression in heterozygous mice. Table shows the
annotations as reported on the Wellcome Trust Sanger Institute
Mouse Genetics Project portal (http://www.sanger.ac.uk/
mouseportal/). B, Restricted tissue expression pattern of Bbx. C,
Expression of Setdb1 in rib cartilage (arrow), as demonstrated by X-
gal staining (blue) of tissue preparation from a 7 week old
heterozygote. D, Expression of Slc38a10 in tracheal cartilage
(arrow) in an 8 week old heterozygote. E, Expression of Spns2in
distal femur and proximal tibia (arrows) in an 8 week old
heterozygote. Corresponding images from wild type (WT) control
mice show background X-gal staining.
(TIF)
Figure S3 Multi-parameter and functional skeletal phenotyping
algorithm. Summary of an unbiased and high-throughput
phenotype screen to identify knockout mice with skeletal
abnormalities and identify new genetic determinants of bone mass
and strength.
(TIF)
Figure S4 Bone structure determined by Faxitron x-ray
microradiography and micro-CT in 100 unselected knockout
mouse strains. The mean value for each parameter obtained from
n=77 female 16 week old WT mice is shown as a horizontal line
with the 2.0 SD reference range limits in grey. Black dots represent
values for individual knockout mice. Grey vertical boxes highlight
the distributions of values from mice of a single strain in which at
least one animal lies outside the reference range, but the mean
value lies within the reference range. Violet vertical boxes and red
squares highlight the distributions of individual values from outlier
strains in which the mean value (horizontal line in violet box) lies
outside the reference range. Gene symbols for outlier strains are
indicated. A–C, Faxitron x-ray microradiography measures of
bone mineral content, bone length and cortical thickness. D–F,
Micro-CT measures of bone volume/tissue volume (BV/TV),
trabecular number (Tb.N) and trabecular thickness (Tb.Th).
(TIF)
Figure S5 Bone strength determined by destruction 3-point bend
testing in 100 unselected knockout mouse strains. The mean value
for each parameter obtained from n=77 female 16 week old WT
mice is shown as a horizontal line with the 2.0SD reference range
limits shaded in grey. Black dots represent values for individual
knockout mice. Grey vertical boxes highlight the distributions of
values from mice of a single strain in which at least one animal lies
outside the reference range, but the mean value lies within the
reference range. Violet vertical boxes and red squares highlight the
distributions of individual values from outlier strains in which the
mean value (horizontal line in violet box) lies outside the reference
range. Gene symbols for outlier strains are indicated. A–F, Yield
load, maximum load, fracture load, stiffness, the proportion of
energy dissipated at maximum load, and the proportion of energy
dissipated at fracture.
(TIF)
Nine New Genetic Determinants of Bone Strength
PLoS Genetics | www.plosgenetics.org 11 August 2012 | Volume 8 | Issue 8 | e1002858
Figure S6 Relationship between bone structure and strength.
In each graph individual wild-type mice are identified by black
spots. The 10 strains with major phenotypes are identified by red
squares and gene symbols. The 2.0SD reference range for each
variable is represented by the grey box. Pearson correlation
coefficients for significant relationships are indicated and blue
lines demonstrate significant linear correlations. A–C, Biome-
chanical and Faxitron parameters. Scatter graphs showing each
of the six biomechanical parameters (yield load, maximum load,
fracture load, stiffness, proportion of energy dissipated at
maximum load, proportion of energy dissipated at fracture)
plotted versus each of the three structural parameters (median
grey value, cortical thickness, bone length) obtained by Faxitron
x-ray microradiography. D–F, Biomechanical and micro-CT
parameters. Scatter graphs showing each of the six biomechanical
parameters (yield load, maximum load, fracture load, stiffness,
proportion of energy dissipated at maximum load, proportion of
energy dissipated at fracture) plotted versus each of the three
structural parameters (BV/TV, Tb. N, Tb. Th) obtained by
micro-CT. G–I, Faxitron and micro-CT parameters. Scatter
graphs showing each of the three structural parameters obtained
by micro-CT versus each of the three structural parameters
obtained by Faxitron x-ray microradiography.
(TIF)
Table S1 Phenotype data for all 100 knockout strains. Mean
values (6SD) for all phenotype parameters were determined from
n= 77 WT mice and are highlighted in yellow in the table
header. The mean values (and distance in SD from the C57BL/6
reference mean) are shown for each parameter determined in
each of the 100 mouse strains. Bone volume/tissue volume (BV/
TV), trabecular thickness (Tb.Th) and trabecular number (Tb. N)
were determined by micro-CT and bone mineral content (BMC),
mean length of tibia and ulna, and cortical thickness (C.Th) by
Faxitron x-ray microradiography. Mahalanobis distances were
calculated to account for variance in all six structural parameters
simultaneously and strains with significant values are indicated.
Yield load, maximum load, fracture load, stiffness, the proportion
of energy dissipated at maximum load and proportion of energy
dissipated at fracture were determined by destruction 3-point
bend testing. Note all SD values were rounded to 1 decimal place
and only values .2.0SD outside the reference mean for each
parameter are highlighted in grey. Measures of skeletal
morphology (x-ray), body length, bone mineral density (DEXA)
and serum biochemical parameters (Biochem) of relevance to
bone and mineral metabolism (Ca2+, Mg2+, PO4
32, creatinine
and alkaline phosphatase) were determined as part of the broad
primary phenotype screen conducted by the MGP. Primary
phenotype parameters for which $60% of knockout mice were
outside the 95% reference range are highlighted in grey (http://
www.sanger.ac.uk/mouseportal/). N= normal; ND=not deter-
mined;Q= reduced. Normal expression of deleted genes in bone
and cartilage was determined by whole mount staining for lacZ
reporter gene expression in heterozygous mice as part of the
primary phenotype screen and the outcome of these studies is also
shown. Note that quality control analysis of gene targeting events
performed after completion of these studies identified two strains
(Psmb2 and 5031439G07Rik) that were incorrectly targeted and
did not harbour a knockout allele. Accordingly, neither strain had
an abnormal skeletal phenotype.
(XLSX)
Table S2 Accuracy of methods to identify major phenotypes
affecting the structure and strength of bone. The sensitivities,
specificities and positive and negative predictive values of x-ray
microradiography, micro-CT, Mahalanobis calculations and
broad primary phenotyping are shown.
(DOC)
Acknowledgments
We thank R. Bassett for advice on biomechanical testing and members of
the Sanger Institutes’ ES Cell Mutagenesis Group, Mouse Informatics
Group and Research Support Facility for their support.
Author Contributions
Conceived and designed the experiments: JHDB PIC GRW. Performed
and analyzed Faxitron x-ray microradiography and 3-point bend testing:
AG AHvdS JHDB GRW. Performed and analyzed micro-CT imaging:
HE PIC. Developed methods for image and biomechanical analysis: AB
JHDB GRW. Oversaw the production and quality assurance of mice, and
the generation and analysis of phenotyping data for the Sanger MGP:
RR-S JKW ER. Organized and managed collection and distribution of
samples from WT and knockout mice: DS. Performed Mahalanobis
distance calculations and principal component analysis and provided
statistical advice: RMJ MJC. Inspired the work and wrote the paper: GRW
PIC JHDB. Read and provided comments on the final manuscript: JHDB
AG JKW HE RMJ AHvdS RR-S ER DS AB MJC PIC GRW.
References
1. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, et al. (1999)
Effects of recombinant leptin therapy in a child with congenital leptin deficiency.
N Engl J Med 341: 879–884.
2. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, et al. (1997)
Congenital leptin deficiency is associated with severe early-onset obesity in
humans. Nature 387: 903–908.
3. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, et al. (2006)
Switching from insulin to oral sulfonylureas in patients with diabetes due to
Kir6.2 mutations. N Engl J Med 355: 467–477.
4. Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, et al. (1996) Mutations in
the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the
young (MODY3). Nature 384: 455–458.
5. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, et al.
(2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a
novel cystine knot-containing protein. Am J Hum Genet 68: 577–589.
6. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, et al.
(1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1.
Science 276: 404–407.
7. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, et al. (2001) LDL
receptor-related protein 5 (LRP5) affects bone accrual and eye development.
Cell 107: 513–523.
8. Collins FS, Rossant J, Wurst W (2007) A mouse for all reasons. Cell 128: 9–13.
9. Skarnes WC, Rosen B, West AP, Koutsourakis M, Bushell W, et al. (2011) A
conditional knockout resource for the genome-wide study of mouse gene
function. Nature 474: 337–342.
10. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability
associated with osteoporotic fractures. Osteoporos Int 17: 1726–1733.
11. Ralston SH, Uitterlinden AG (2010) Genetics of osteoporosis. Endocr Rev 31:
629–662.
12. Rivadeneira F, Styrkarsdottir U, Estrada K, Halldorsson BV, Hsu YH, et al.
(2009) Twenty bone-mineral-density loci identified by large-scale meta-analysis
of genome-wide association studies. Nat Genet 41: 1199–1206.
13. Cirulli ET, Goldstein DB (2010) Uncovering the roles of rare variants in common
disease through whole-genome sequencing. Nat Rev Genet 11: 415–425.
14. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, et al. (2000)
Fracture risk reduction with alendronate in women with osteoporosis: the
Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:
4118–4124.
15. Mackey DC, Black DM, Bauer DC, McCloskey EV, Eastell R, et al. (2011)
Effects of antiresorptive treatment on non-vertebral fracture outcomes. J Bone
Miner Res 26: 2411–2418.
16. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, et al. (2002) High bone density
due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346: 1513–
1521.
Nine New Genetic Determinants of Bone Strength
PLoS Genetics | www.plosgenetics.org 12 August 2012 | Volume 8 | Issue 8 | e1002858
17. Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future.
Lancet 377: 1276–1287.
18. Brown SD, Chambon P, de Angelis MH (2005) EMPReSS: standardized
phenotype screens for functional annotation of the mouse genome. Nat Genet
37: 1155.
19. Justice MJ (2008) Removing the cloak of invisibility: phenotyping the mouse. Dis
Model Mech 1: 109–112.
20. Karp NA, Baker LA, Gerdin AK, Adams NC, Ramirez-Solis R, et al. (2010)
Optimising experimental design for high-throughput phenotyping in mice: a
case study. Mamm Genome 21: 467–476.
21. Hardisty-Hughes RE, Parker A, Brown SD (2010) A hearing and vestibular
phenotyping pipeline to identify mouse mutants with hearing impairment. Nat
Protoc 5: 177–190.
22. Boskey AL, Moore DJ, Amling M, Canalis E, Delany AM (2003) Infrared
analysis of the mineral and matrix in bones of osteonectin-null mice and their
wildtype controls. J Bone Miner Res 18: 1005–1011.
23. Delany AM, Amling M, Priemel M, Howe C, Baron R, et al. (2000) Osteopenia
and decreased bone formation in osteonectin-deficient mice. J Clin Invest 105:
915–923.
24. Everitt B, editor (2005) An R and S-PLUS Companion to Multivariate Analysis.
London: Springer.
25. Mitchell AFS, Krzanowski WJ (1985) The Mahalanobis distance and elliptic
distributions. Biometrika 72: 464–467.
26. Rousseeuw PJ (1985) Multivariate estimation with high breakdown point; W.
Grossmann GP, I. Vinceze, and W. Wertz, Eds., editor. The Netherlands:
Reidel. 283–297.
27. Rousseeuw PJ, Van Zomeren BC (1990) Unmasking Multivariate Outliers and
Leverage Points. Journal of the American Statistical Association 85: 633–639.
28. Ammann P, Rizzoli R (2003) Bone strength and its determinants. Osteoporos Int
14 Suppl 3: S13–18.
29. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and
activation. Nature 423: 337–342.
30. Harada S, Rodan GA (2003) Control of osteoblast function and regulation of
bone mass. Nature 423: 349–355.
31. Dickenson RP, Hutton WC, Stott JR (1981) The mechanical properties of bone
in osteoporosis. J Bone Joint Surg Br 63-B: 233–238.
32. Marchler-Bauer A, Anderson JB, Chitsaz F, Derbyshire MK, DeWeese-Scott C,
et al. (2009) CDD: specific functional annotation with the Conserved Domain
Database. Nucleic Acids Res 37: D205–210.
33. Dailey L, Basilico C (2001) Coevolution of HMG domains and homeodomains
and the generation of transcriptional regulation by Sox/POU complexes. J Cell
Physiol 186: 315–328.
34. Laudet V, Stehelin D, Clevers H (1993) Ancestry and diversity of the HMG box
superfamily. Nucleic Acids Res 21: 2493–2501.
35. Love JJ, Li X, Case DA, Giese K, Grosschedl R, et al. (1995) Structural basis for
DNA bending by the architectural transcription factor LEF-1. Nature 376: 791–
795.
36. Pohler JR, Norman DG, Bramham J, Bianchi ME, Lilley DM (1998) HMG box
proteins bind to four-way DNA junctions in their open conformation. EMBO J
17: 817–826.
37. Bernard P, Tang P, Liu S, Dewing P, Harley VR, et al. (2003) Dimerization of
SOX9 is required for chondrogenesis, but not for sex determination. Hum Mol
Genet 12: 1755–1765.
38. Mundlos S, Olsen BR (1997) Heritable diseases of the skeleton. Part I: Molecular
insights into skeletal development-transcription factors and signaling pathways.
FASEB J 11: 125–132.
39. MacDonald BT, Tamai K, He X (2009) Wnt/beta-catenin signaling:
components, mechanisms, and diseases. Dev Cell 17: 9–26.
40. Balemans W, Van Hul W (2007) The genetics of low-density lipoprotein
receptor-related protein 5 in bone: a story of extremes. Endocrinology 148:
2622–2629.
41. Baron R, Rawadi G (2007) Wnt signaling and the regulation of bone mass. Curr
Osteoporos Rep 5: 73–80.
42. Chan A, van Bezooijen RL, Lowik CW (2007) A new paradigm in the treatment
of osteoporosis: Wnt pathway proteins and their antagonists. Curr Opin Investig
Drugs 8: 293–298.
43. Luyten FP, Tylzanowski P, Lories RJ (2009) Wnt signaling and osteoarthritis.
Bone 44: 522–527.
44. Giangreco A, Jensen KB, Takai Y, Miyoshi J, Watt FM (2009) Necl2 regulates
epidermal adhesion and wound repair. Development 136: 3505–3514.
45. Kuramochi M, Fukuhara H, Nobukuni T, Kanbe T, Maruyama T, et al. (2001)
TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat
Genet 27: 427–430.
46. Biederer T, Sara Y, Mozhayeva M, Atasoy D, Liu X, et al. (2002) SynCAM, a
synaptic adhesion molecule that drives synapse assembly. Science 297: 1525–
1531.
47. Takayanagi Y, Fujita E, Yu Z, Yamagata T, Momoi MY, et al. (2010)
Impairment of social and emotional behaviors in Cadm1-knockout mice.
Biochem Biophys Res Commun 396: 703–708.
48. Giangreco A, Hoste E, Takai Y, Rosewell I, Watt FM (2012) Epidermal Cadm1
expression promotes autoimmune alopecia via enhanced T cell adhesion and
cytotoxicity. J Immunol 188: 1514–1522.
49. Ito A, Hagiyama M, Oonuma J (2008) Nerve-mast cell and smooth muscle-mast
cell interaction mediated by cell adhesion molecule-1, CADM1. J Smooth
Muscle Res 44: 83–93.
50. Fujita E, Kouroku Y, Ozeki S, Tanabe Y, Toyama Y, et al. (2006) Oligo-
astheno-teratozoospermia in mice lacking RA175/TSLC1/SynCAM/IGSF4A,
a cell adhesion molecule in the immunoglobulin superfamily. Mol Cell Biol 26:
718–726.
51. Rauch F, Glorieux FH (2004) Osteogenesis imperfecta. Lancet 363: 1377–1385.
52. Tatibana M, Kita K, Taira M, Ishijima S, Sonoda T, et al. (1995) Mammalian
phosphoribosyl-pyrophosphate synthetase. Adv Enzyme Regul 35: 229–249.
53. Katashima R, Iwahana H, Fujimura M, Yamaoka T, Itakura M (1998)
Assignment of the human phosphoribosylpyrophosphate synthetase-associated
protein 41 gene (PRPSAP2) to 17p11.2–p12. Genomics 54: 180–181.
54. Both J, Wu T, Bras J, Schaap GR, Baas F, et al. (2012) Identification of novel
candidate oncogenes in chromosome region 17p11.2–p12 in human osteosar-
coma. PLoS One 7: e30907.
55. Sundberg BE, Waag E, Jacobsson JA, Stephansson O, Rumaks J, et al. (2008)
The evolutionary history and tissue mapping of amino acid transporters
belonging to solute carrier families SLC32, SLC36, and SLC38. J Mol Neurosci
35: 179–193.
56. Franchi-Gazzola R, Dall’Asta V, Sala R, Visigalli R, Bevilacqua E, et al. (2006)
The role of the neutral amino acid transporter SNAT2 in cell volume regulation.
Acta Physiol (Oxf) 187: 273–283.
57. Kronenberg HM (2003) Developmental regulation of the growth plate. Nature
423: 332–336.
58. Hiraoka S, Furuichi T, Nishimura G, Shibata S, Yanagishita M, et al. (2007)
Nucleotide-sugar transporter SLC35D1 is critical to chondroitin sulfate synthesis
in cartilage and skeletal development in mouse and human. Nat Med 13: 1363–
1367.
59. Superti-Furga A, Hastbacka J, Rossi A, van der Harten JJ, Wilcox WR, et al.
(1996) A family of chondrodysplasias caused by mutations in the diastrophic
dysplasia sulfate transporter gene and associated with impaired sulfation of
proteoglycans. Ann N Y Acad Sci 785: 195–201.
60. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, et al. (2008) Targeted
deletion of the sclerostin gene in mice results in increased bone formation and
bone strength. J Bone Miner Res 23: 860–869.
61. Akhter MP, Wells DJ, Short SJ, Cullen DM, Johnson ML, et al. (2004) Bone
biomechanical properties in LRP5 mutant mice. Bone 35: 162–169.
62. Lee SW, Cho YS, Na JM, Park UH, Kang M, et al. (2010) ASXL1 represses
retinoic acid receptor-mediated transcription through associating with HP1 and
LSD1. J Biol Chem 285: 18–29.
63. Fisher CL, Lee I, Bloyer S, Bozza S, Chevalier J, et al. (2010) Additional sex
combs-like 1 belongs to the enhancer of trithorax and polycomb group and
genetically interacts with Cbx2 in mice. Dev Biol 337: 9–15.
64. Wellik DM (2007) Hox patterning of the vertebrate axial skeleton. Dev Dyn 236:
2454–2463.
65. Williams JA, Kondo N, Okabe T, Takeshita N, Pilchak DM, et al. (2009)
Retinoic acid receptors are required for skeletal growth, matrix homeostasis and
growth plate function in postnatal mouse. Dev Biol 328: 315–327.
66. Hoischen A, van Bon BW, Rodriguez-Santiago B, Gilissen C, Vissers LE, et al.
(2011) De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome.
Nat Genet 43: 729–731.
67. Schultz DC, Ayyanathan K, Negorev D, Maul GG, Rauscher FJ, 3rd (2002)
SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltrans-
ferase that contributes to HP1-mediated silencing of euchromatic genes by
KRAB zinc-finger proteins. Genes Dev 16: 919–932.
68. Yang L, Xia L, Wu DY, Wang H, Chansky HA, et al. (2002) Molecular cloning
of ESET, a novel histone H3-specific methyltransferase that interacts with ERG
transcription factor. Oncogene 21: 148–152.
69. Nifuji A, Ideno H, Ohyama Y, Takanabe R, Araki R, et al. (2010) Nemo-like
kinase (NLK) expression in osteoblastic cells and suppression of osteoblastic
differentiation. Exp Cell Res 316: 1127–1136.
70. Takada I, Mihara M, Suzawa M, Ohtake F, Kobayashi S, et al. (2007) A histone
lysine methyltransferase activated by non-canonical Wnt signalling suppresses
PPAR-gamma transactivation. Nat Cell Biol 9: 1273–1285.
71. Hisano Y, Kobayashi N, Kawahara A, Yamaguchi A, Nishi T (2011) The
sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the
phosphorylated form of the immunomodulating agent FTY720. J Biol Chem
286: 1758–1766.
72. Ishii M, Egen JG, Klauschen F, Meier-Schellersheim M, Saeki Y, et al. (2009)
Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone
homeostasis. Nature 458: 524–528.
73. Ishii T, Shimazu Y, Nishiyama I, Kikuta J, Ishii M (2011) The role of
sphingosine 1-phosphate in migration of osteoclast precursors; an application of
intravital two-photon microscopy. Mol Cells 31: 399–403.
74. Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ (2008) Regulation of
bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine
sphingosine-1-phosphate. Proc Natl Acad Sci U S A 105: 20764–20769.
75. Ryu J, Kim HJ, Chang EJ, Huang H, Banno Y, et al. (2006) Sphingosine 1-
phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast
coupling. EMBO J 25: 5840–5851.
76. Chu Y, Yang X (2011) SUMO E3 ligase activity of TRIM proteins. Oncogene
30: 1108–1116.
Nine New Genetic Determinants of Bone Strength
PLoS Genetics | www.plosgenetics.org 13 August 2012 | Volume 8 | Issue 8 | e1002858
77. Napolitano LM, Jaffray EG, Hay RT, Meroni G (2011) Functional
interactions between ubiquitin E2 enzymes and TRIM proteins. Biochem J
434: 309–319.
78. Ozato K, Shin DM, Chang TH, Morse HC, 3rd (2008) TRIM family proteins
and their emerging roles in innate immunity. Nat Rev Immunol 8: 849–860.
79. Wang Y, Li Y, Qi X, Yuan W, Ai J, et al. (2004) TRIM45, a novel human
RBCC/TRIM protein, inhibits transcriptional activities of ElK-1 and AP-1.
Biochem Biophys Res Commun 323: 9–16.
80. Komori T (2006) Regulation of osteoblast differentiation by transcription
factors. J Cell Biochem 99: 1233–1239.
81. Wagner EF (2010) Bone development and inflammatory disease is regulated by
AP-1 (Fos/Jun). Ann Rheum Dis 69 Suppl 1: i86–88.
82. Richards JB, Rivadeneira F, Inouye M, Pastinen TM, Soranzo N, et al. (2008)
Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide
association study. Lancet 371: 1505–1512.
83. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters
GB, et al. (2008) Multiple genetic loci for bone mineral density and fractures.
N Engl J Med 358: 2355–2365.
84. Estrada K, Styrkarsdottir U, Evangelou E, Hsu YH, Duncan EL, et al. (2012)
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals
14 loci associated with risk of fracture. Nat Genet 44: 491–501.
85. Bassett JH, Boyde A, Howell PG, Bassett RH, Galliford TM, et al. (2010)
Optimal bone strength and mineralization requires the type 2 iodothyronine
deiodinase in osteoblasts. Proc Natl Acad Sci U S A 107: 7604–7609.
86. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, et al. (1987)
Bone histomorphometry: standardization of nomenclature, symbols, and units.
Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone
Miner Res 2: 595–610.
87. Venables WN, Ripley BD (2002) Modern Applied Statistics with S New York,
NY, USA: Springer.
Nine New Genetic Determinants of Bone Strength
PLoS Genetics | www.plosgenetics.org 14 August 2012 | Volume 8 | Issue 8 | e1002858
